The ASCO Post

11/21/2025

🔬New CAPS analysis: Mild dilation of the main pancreatic duct is an independent risk factor for progression to pancreatic cancer in high-risk individuals. Risk reached 16% at 5 yrs and 26% at 10 yrs.
✍️ Marcia Irene Canto, MD, MHS
🔗 https://ascopost.com/news/november-2025/pancreatic-cancer-mild-duct-dilation-may-serve-as-early-indicator-in-high-risk-patients/

11/20/2025

Meta-analysis (JAMA Network Open)revealed first-line PARPi maintenance after platinum chemo in advanced ovarian cancer improves PFS but no OS benefit, higher toxicity
Experts urge personalized strategy
🔷Tibor A. Zwimpfer, MD
🔷Stamatios Petousis, PhD, MD
https://ascopost.com/news/november-2025/advanced-epithelial-ovarian-cancer-first-line-parp-inhibitor-maintenance-therapy-and-survival/

11/18/2025

🆕 DESTINY-Breast09 data in HER2+ mBC:
• 44% reduced risk of progression/death
• PFS: 40.7 mo
• ORR: 85%
T-DXd + pertuzumab may redefine first-line treatment, per Sara Tolaney et al


🔗 https://ascopost.com/news/november-2025/t-dxd-plus-pertuzumab-in-her2-positive-advanced-or-metastatic-breast-cancer/

11/14/2025

BART trial ASTRO25: Adjuvant Radiation Therapy after cystectomy reduced locoregional recurrence in pts w/ high-risk muscle-invasive bladder cancer. Modern IMRT to the pelvis safe after surgery—supports IO integration in trials
🔷 Presenter Vedang Murthy, MD
🔗 https://ascopost.com/news/november-2025/safety-and-benefit-of-radiation-therapy-for-high-risk-muscle-invasive-bladder-cancer/

11/13/2025

The National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology to be integrated int Open Evidence's medical AI platform so clinicians can access trusted, evidence-based cancer care recommendations for decision-making support via natural language search.

➡️https://ascopost.com/news/november-2025/nccn-guidelines-to-be-integrated-into-openevidence-medical-ai-platform/

08/07/2025

Avutometinib Plus Defactinib in Recurrent Low‑Grade Serous Ovarian Cancer

The Leukemia & Lymphoma Society (LLS) is rebranding in advance of Blood Cancer Awareness Month in September.

08/06/2025

Avutometinib Plus Defactinib in Recurrent Low‑Grade Serous Ovarian Cancer
https://ascopost.com/news/august-2025/avutometinib-plus-defactinib-in-recurrent-low-grade-serous-ovarian-cancer/

In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with ...

08/01/2025

Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort

As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benef...

07/31/2025

ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality

Being a firefighter increased the mortality risk for most cancers, especially for skin and kidney cancers, according to the results from a large prospective study by the American Cancer Society. Incre...

07/28/2025

HER3-targeted patritumab deruxtecan shows efficacy in leptomeningeal metastases from solid tumors in Phase II TUXEDO-3 trial

The HER3-directed antibody-drug conjugate patritumab deruxtecan demonstrated clinical efficacy in treating patients with leptomeningeal metastatic disease of solid tumors, according to findings from a...

07/25/2025

American Cancer Society Names New CEO

“He is a bold, mission-driven leader with integrity and the proven ability to align purpose with performance. His leadership, passion, and deep belief in the urgency of our work will make a difference...

07/23/2025

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

“Steroids were the biggest predictor of why certain immunotherapies may not be effective, even when considering multiple other factors such as stage and progression of the disease,” said researchers.